Kalaris (KLRS) Director Jovan-Embiricos Morana Receives 9,000-Share Option Grant

What Happened Jovan-Embiricos Morana, a director of Kalaris Therapeutics, was granted a derivative award covering 9,000 shares on June 3, 2026. The grant is reported as an acquisition (award) at $0.00 per share (no immediate cash paid or received). This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-03; filing posted 2026-06-04 (no late filing indicated).
• Amount: Options/award covering 9,000 shares; reported price $0.00 and reported value $0 (derivative security).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option was granted 6/3/2026. The underlying shares vest in full on the earlier of (i) June 3, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
• Transaction code: A (award/grant of derivative securities).

Context This was a stock-based compensation award to a director, not an exercise or sale. The award does not create immediate proceeds or signify an immediate buy/sell signal — it simply gives the director the right to acquire shares if vesting conditions are met. Vesting is time- and service-based, so the shares would only become available if Morana remains in service through the vesting date or the 2027 annual meeting.